← Eichor
Condition: Locally Advanced Solid Tumors Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Locally Advanced Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+
Phase 1 · 1 location(s) · China Medical University, China · NCT06013111A Study of TYK-00540 in Adult Patients With Solid Tumors
Phase 1 · 1 location(s) · TYK Medicines, Inc · NCT06246071A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harbor
Phase 2 · 31 location(s) · Allist Pharmaceuticals, Inc. · NCT06008288A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
Phase 1/Phase 2 · 1 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT05991583Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusi
Phase N/A · 76 location(s) · Bayer · NCT04142437Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT07156253A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Phase 1 · 3 location(s) · Proviva Therapeutics, Inc. · NCT06190886A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of
Phase 1/Phase 2 · 12 location(s) · Ipsen · NCT07213817A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Phase 1/Phase 2 · 2 location(s) · RemeGen Co., Ltd. · NCT05205850A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06493864A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Canc
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06500052A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic
Phase 1/Phase 2 · 31 location(s) · RemeGen Co., Ltd. · NCT06016062Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT06666270A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Phase 1 · 21 location(s) · Nuvalent Inc. · NCT06521554BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · 3 location(s) · Avacta Life Sciences Ltd · NCT07454642Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06418061Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Co
Phase 1 · 12 location(s) · Teva Branded Pharmaceutical Products R&D LLC · NCT06480552IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Soli
Phase 1/Phase 2 · 14 location(s) · InxMed (Shanghai) Co., Ltd. · NCT07441174A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Phase 1/Phase 2 · 12 location(s) · Vivace Therapeutics, Inc · NCT04665206Imaging of Solid Tumors Using 18F-TRX
Phase 1 · 1 location(s) · Rahul Aggarwal · NCT06942104A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 3 location(s) · ABL Bio, Inc. · NCT06126666RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
Phase 1 · 1 location(s) · RemeGen Co., Ltd. · NCT05940896Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Phase 1 · 9 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT06963281Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/Phase 2 · 14 location(s) · Salubris Biotherapeutics Inc · NCT06667960
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.